We demonstrated that lethal pancreatic cancer driven by c-MYC can be inhibited with the c-MYC-mRNA drug, 3′UTRMYC1-18, in a dose-dependent, titratable manner to achieve a remarkably significant survival outcome. This evidence concerns the gene MYC and familial pancreatic carcinoma.